Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...1920212223242526272829...123124»
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    A Study of Combination Therapy with SBRT for HCC with Macrovascular Invasion at Our Institution. (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_2181;    
    SBRT for MVI-HCC was performed safely and effectively at our institution. There were no significant differences in OS despite the different treatments depending on liver function and tumor occupancy.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    A case of successful Lenvatinib for bone metastases from HCC complicated by psoriasiform dermatitis (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_2100;    
    On the other hand, anti-PD-L1 antibody-induced psoriasis-like dermatitis has been shown to be induced by blockade of PDL1 signaling on Langerhans cells. Since multikinase inhibitors are different from these mechanisms, they may be introduced as a 2nd line therapy without psoriasis exacerbation.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Pre-Sarcopenia predicts the outcome of hepatocellular carcinoma patients with first-line Lenvatinib (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_2084;    
    Since multikinase inhibitors are different from these mechanisms, they may be introduced as a 2nd line therapy without psoriasis exacerbation. In clinical practice, pre?sarcopenia was shown to be a significant prognostic factor in patients treated with first-line lenvatinib for unresectable HCC.
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    A case of rhabdomyolysis and acute renal failure due to atezolizumab plus bevacizumab therapy (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_2074;    
    In this case, the patient had undergone the 10th course as an outpatient without any problems except for poor background liver function, but after the 11th course, the disease rapidly worsened with the sudden onset of Influenza A infection and rhabdomyolysis. Atez/Bev for patients with poor liver function requires careful judgment, including the indications.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Characteristics of hepatocellular carcinoma treated with drug therapy followed by conversion therapy (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_2053;    
    In our case, immediate high-dose corticosteroids therapy may help improvement of patient's neurological symptoms. Sixty-three with BCLC-B stage HCC who started drug therapy at our hospital between January 2016 and March 2023,age 77 years
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    A case of hepatocellular carcinoma cured by drug therapy, microwave ablation, and c-TACE (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_1993;    
    We experienced a case of intermediate-stage hepatocellular carcinoma in which ABC-Conversion (Atezolizumab plus Bevacizumab Curative Conversion) was performed. In the IMbrave150 study, the response rate for intermediate-stage hepatocellular carcinoma in the atezolizumab plus bevacizumab group was 44%, indicating that the treatment has a strong tumor shrinkage effect, and it is necessary to perform treatment while timing conversion.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Hepatocellular carcinoma with PV invasion and L/N metastasis cured with multidisciplinary treatment (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_1721;    
    AFP remained still high (8,000 level), then Lenvatinib was administrated with 12 mg/day and AFP decreased to 3,000 level, but interrupted and reduced to 8mg/day due to thrombocytopenia, and interrupted again due to duodenal bleeding...Instead, Sorafenib was administrated with the dosage of 800 mg/day, but interrupted due to high fever 10 days later... Multidisciplinary treatment with combination of resection, HAIC, irradiation and systemic chemotherapy seemed to be effective in this advanced case with PV invasion and L/N metastasis.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Changes in systemic chemotherapy for unresectable HCC and its effect on overall survival (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_1471;    
    As a result, the number of available regimens increased, and the number of used lines increased, resulting in improved OS in patients with good liver reserve function. The ICI regimen, which is expected to be more effective, has become the mainstream regimen, and is expected to further improve OS in the future.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    The efficacy and safety of atezolizumab/bevacizumab versus lenvatinib for hepatocellular carcinoma (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_1340;    
    In this real-world study, ATE/BEV showed significantly superior efficacy in terms of survival time when compared with LENV in unresectable HCC patients regardless of the cause of hepatitis. The safety in terms of liver function preservation was not different between the both treatment groups.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    First-Line Lenvatinib  () -  Jan 6, 2024 - Abstract #APASL2024APASL_1173;    
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    IL-6 is a useful biomarker for selection of systemic therapies in hepatocellular carcinoma (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_894;    
    Among patients who received Atezo+Bev or Lenvatinib (Len) as a first-line systemic therapy at our hospital, 96 patients were enrolled in the HCC group after propensity score matching, while 20 tumor-free patients were enrolled as a control group... Serum IL-6 level is a useful predictor of therapeutic benefit from Atezo+Bev treatment.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Lenvatinib as 2nd line in post-immunotherapy for hepatocellular carcinoma (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_714;    
    LEN was useful as second-line therapy for HCC patients who did not respond to AteBev treatment. Patients whose FGF pathway is activated by AteBev treatment are expected to respond to LEN.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Impact of elevated indirect bilirubin in systemic treatment for hepatocellular carcinoma (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_710;    
    Prognoses in BH patients receiving systemic therapy for HCC may be better than their non-BH counterparts. Larger, multicenter studies are desirable to elucidate the impact of BH on outcomes in HCC.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Lenvatinib modifies the tumor microenvironment in HCC and assembles GZMK+CD8 T cells (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_538;    
    This transformation is significant, yet lenvatinibtreated HCC might still be "altered-excluded" due to the physical barriers created by extracellular matrix (ECM). Combining treatments for ECM may enhance the effectiveness of immune cells recruited by lenvatinib, especially when used in combination with ICI."
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Combinatorial Hypofractionated Radiotherapy and Pembrolizumab in Anaplastic Thyroid Cancer. (Pubmed Central) -  Jan 5, 2024   
    Conclusions Herein, we reported a case series of 5 patients with ATC, with 2 long-term survivors who were treated with surgical debulking followed by QUAD-shot RT and pembrolizumab, possibly due to synergy of local and systemic treatments in activating anti-tumour immunogenic cytotoxicity. This regimen warrants further investigation in a larger cohort of patients.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Surgery:  Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery. (Pubmed Central) -  Jan 3, 2024   
    The addition of RT to TACE and LEN was safe, and might improve clinical outcomes of patients with advanced HCC, which needs conformation from further studies. This retrospective cohort study included HCC patients who, after undergoing failed postoperative adjuvant lenvatinib therapy, received intravenous camrelizumab 200 mg every 3 weeks (C group, n = 97), camrelizumab plus oral apatinib 250 mg daily (C+A group, n = 125), camrelizumab plus oral lenvatinib 12 mg daily (for bodyweight ?60 kg)/lenvatinib 8 mg daily (for bodyweight <60
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Metastases:  A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer (clinicaltrials.gov) -  Jan 1, 2024   
    P1/2,  N=43, Recruiting, 
    Caution should be exercised for LEN-treated patients with BCLC advanced stage or those receiving the full dose of LEN. Not yet recruiting --> Recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), VIC-1911 / VITRAC Therap
    Enrollment open, Trial initiation date:  Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC (clinicaltrials.gov) -  Dec 27, 2023   
    P=N/A,  N=30, Recruiting, 
    Trial completion date: Nov 2023 --> Apr 2024 Not yet recruiting --> Recruiting | Initiation date: Feb 2023 --> Jul 2023